HK1030540A1 - Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp - Google Patents

Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp

Info

Publication number
HK1030540A1
HK1030540A1 HK00108400A HK00108400A HK1030540A1 HK 1030540 A1 HK1030540 A1 HK 1030540A1 HK 00108400 A HK00108400 A HK 00108400A HK 00108400 A HK00108400 A HK 00108400A HK 1030540 A1 HK1030540 A1 HK 1030540A1
Authority
HK
Hong Kong
Prior art keywords
bmp
gdnf
cells
vivo
neurotrophic factors
Prior art date
Application number
HK00108400A
Other languages
English (en)
Inventor
David C Rueger
Marc F Charette
Ted Ebendal
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of HK1030540A1 publication Critical patent/HK1030540A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
HK00108400A 1997-09-09 2000-12-23 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp HK1030540A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5825897P 1997-09-09 1997-09-09
PCT/US1998/018772 WO1999012560A1 (en) 1997-09-09 1998-09-09 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors

Publications (1)

Publication Number Publication Date
HK1030540A1 true HK1030540A1 (en) 2001-05-11

Family

ID=22015678

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00108400A HK1030540A1 (en) 1997-09-09 2000-12-23 Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp

Country Status (9)

Country Link
EP (1) EP1011711B1 (xx)
JP (3) JP2001515867A (xx)
AT (1) ATE363914T1 (xx)
AU (1) AU749454B2 (xx)
CA (1) CA2303460C (xx)
DE (1) DE69837885T2 (xx)
ES (1) ES2288766T3 (xx)
HK (1) HK1030540A1 (xx)
WO (1) WO1999012560A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301693A1 (en) 1997-09-19 1999-04-01 Klaus Unsicker Cytokines having neurotrophic activity
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
WO2000051980A1 (en) 1999-03-05 2000-09-08 The Procter & Gamble Company C16 unsaturated fp-selective prostaglandins analogs
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
PL2019683T5 (pl) 2006-04-25 2022-12-05 The Regents Of The University Of California Podawanie czynników wzrostu do leczenia zaburzeń OUN
JP7502882B2 (ja) 2020-03-31 2024-06-19 直樹 林田 ポリグルタミンタンパク質凝集抑制剤、及びポリグルタミン病の予防または治療用医薬

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018735A2 (en) * 1994-12-14 1996-06-20 Amgen Boulder Inc. Tgf-beta superfamily type ii receptor having binding affinity for bone morphogenic protein (bmp)
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

Also Published As

Publication number Publication date
CA2303460C (en) 2011-06-21
EP1011711B1 (en) 2007-06-06
JP5550673B2 (ja) 2014-07-16
JP2012131832A (ja) 2012-07-12
JP2001515867A (ja) 2001-09-25
JP5075877B2 (ja) 2012-11-21
EP1011711A1 (en) 2000-06-28
JP2009209152A (ja) 2009-09-17
CA2303460A1 (en) 1999-03-18
WO1999012560A1 (en) 1999-03-18
ES2288766T3 (es) 2008-01-16
AU749454B2 (en) 2002-06-27
DE69837885D1 (de) 2007-07-19
DE69837885T2 (de) 2008-02-07
ATE363914T1 (de) 2007-06-15
AU9475998A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
Wang et al. Use of carnosine as a natural anti-senescence drug for human beings
AU2782499A (en) Isolated stromal cells for use in the treatment of diseases of the central nervous system
GB9807639D0 (en) Anti-inflammatory agents
BR0013905A (pt) Uso de um ingrediente ativo, composição farmacêutica, métodos para induzir secreção g-csf dentro do corpo de um indivìduo, para tratamento terapêutico, para induzir a proliferação ou diferenciação de medula óssea ou células brancas do sangue em um indivìduo, para a prevenção ou tratamento de leucopenia, para a prevenção ou tratamento de efeitos colaterais tóxicos de uma droga, para inibir o crescimento anormal de células, para o tratamento de câncer, e, uso de a3rag
BR0307871A (pt) Proteìnas contendo domìnio de folistatina
WO2001064238A3 (en) Methods and compositions for regulating adipocytes
BR0315645A (pt) Polipetìdeos de fusão de actrib e seus usos
IL180528A0 (en) Pharmaceutical formulations for treating mitochondrial disorders
PL339745A1 (en) Agonists of apolipoprotein a-1 and their application in treating dislipidemic disorders
IL147990A0 (en) Multipotent adult stem cells and methods for isolation
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
BR0309623A (pt) Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas
WO1999010004A3 (en) Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
HK1030540A1 (en) Synergistic effects of op/bmp morphogens and gdnf/ngf neurotrophic factors op/bmp
IL123642A (en) Pharmaceutical compositions comprising mononuclear phagocytes to promote axonal regeneration
Gerhke et al. Potential of the use of an antioxidant compound to promote peripheral nerve regeneration after injury
WO2000015246A3 (en) Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
WO2007014156A3 (en) Fibroblast growth factor-2 promotes neurogenesis and neuroprotection and prolongs survival in huntington's disease
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
AU7500200A (en) Combined therapies for atherosclerosis treatment
Smith The pineal gland and its neurosecretory product, melatonin.
US20130281400A1 (en) Metabolic Downregulation for Cell Survival
Vvedenskiy et al. Effect of Cryopreserved Cord Blood Serum Administration on Structural Changes of Joints During Induced Gonarthrosis in Rats
Rosenberg-Schaffer An in vitro study of the effects of methylprednisolone on lesioned and uninjured mammalian spinal cord neurons.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160909